Besides clinical candidates, what else is GeoVax working on?
We are also conducting preclinical research on the impact of adding adjuvants (immune system stimulants) to our vaccine components to investigate whether they can improve the effectiveness of our vaccine candidates. This work is being funded by the NIH through an Integrated Preclinical/Clinical AIDS Vaccine Development Grant (IPCAVD) to GeoVax. If the activities funded by the IPCAVD grant are successful, we may decide to initiate a secondary clinical program for the development of the next generation of our HIV/AIDS vaccines.
